ACS

The American Cancer Society today lowered the recommended age for screening patients at average risk for the disease to 45 from 50 years old.

With only one test FDA-approved for primary hrHPV screening, groups express concern about feasibility of moving away from co-testing

In a letter to congressional leaders, the groups said they "believe strongly" that the FDA should play a critical role in developing a modernized framework.